Google’s Isomorphic Labs Raises $5B, 2.4x Its May Round

Isomorphic Labs, the Alphabet drug-discovery company led by Demis Hassabis, has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, the company said in a release on 17 November; Bloomberg also reported the round. Andreessen Horowitz and several other new investors joined, with continued significant investment from Alphabet.

Our number: the round is about 2.4 times the $2.1 billion Isomorphic raised in May, and takes its announced external funding to $7.7 billion in under 20 months, by our arithmetic. About 65% of that total arrived in this one round.

Business Pill · Burn Rate

An evergreen Business Engineer explainer on burn rate: how fast a company spends cash and how long it lasts. It teaches the general idea only and does not discuss Isomorphic Labs.

The key insight: As we read the releases, Isomorphic is now funded mainly by equity rather than by partner cash: the $5 billion round is more than 60 times the $82.5 million Lilly and Novartis paid upfront in 2024, by our arithmetic, and the release ties the money to taking its first programs towards clinical trials.

Who Invested and What the Money Is For

All existing investors took part, the release says: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Greenoaks and Sequoia Capital co-led what the company calls an oversubscribed round.

The release says the money will go to maturing IsoDDE, its drug design engine, expanding into new biology, building a partner ecosystem on mechanistic disease biology, and building global infrastructure for AI-led bioengineering. It says proceeds will also support its build of AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.

Hassabis, Founder and CEO, said the round lets the company drive “our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

Isomorphic Labs’ three announced external rounds: $600 million (31 March 2025), $2.1 billion (12 May 202
Isomorphic Labs’ three announced external rounds: $600 million (31 March 2025), $2.1 billion (12 May 2026) and $5 billion (17 November 2026), from the company’s releases. The 2.4x ratio and the $7.7 billion total are our arithmetic.

Where the Pipeline Stands

The release says Isomorphic is seeing “positive preclinical results, both for internal programs in oncology and immunology and with partners, setting the stage for clinical entry.” It gives no date for a first clinical trial in the text we read.

Max Jaderberg, President, said: “Every week we are making repeatable scientific advancements enabled by our models.”

The company says it is headquartered in London, with offices in Cambridge, Massachusetts and Lausanne, Switzerland, and runs partnered programs alongside wholly-owned internal programs.

Three Rounds in Under 20 Months

Isomorphic announced its first external round, $600 million led by Thrive Capital, on 31 March 2025. Its $2.1 billion Series B, also led by Thrive, followed on 12 May 2026, with MGX, Temasek, CapitalG and the UK Sovereign AI Fund as new investors.

The Series C came 189 days after the Series B, by our arithmetic, and is about 8.3 times the first round. None of the three releases we read gives a valuation. On 4 November, Bloomberg reported that Isomorphic was in talks to raise about $5 billion at a valuation of about $50 billion, according to people familiar with the matter.

Equity Against Pharma Deal Cash

In January 2024 Isomorphic said its Eli Lilly and Novartis collaborations could be worth nearly $3 billion to it, excluding royalties, with $45 million upfront from Lilly and $37.5 million upfront from Novartis. Novartis expanded its deal in February 2025, and Johnson & Johnson signed a research collaboration in January 2026, the company says.

By our arithmetic, the $5 billion round is more than 60 times the $82.5 million of those two upfront payments, and more than 1.6 times the nearly $3 billion of potential deal value. The upfronts equal about 1.1% of the $7.7 billion raised.

The round is about 15 times the eight healthcare AI rounds of $20 million or more we counted from 1 October to 4 November, which totalled $332.5 million. In October, drugmakers attached about $3.8 billion of potential milestone payments to AI partners in one week, by our arithmetic, as we reported on 20 October.

The Structural Read

As we read the release, the money goes into infrastructure as much as molecules: the engine, new biology models, a partner ecosystem and clinical development infrastructure are all named uses of proceeds.

As we read the three releases, the investor base widened at each step: Thrive Capital led the first two rounds, while Greenoaks and Sequoia Capital co-led this one, with Andreessen Horowitz new and all existing investors returning.

Sir Demis Hassabis, Founder and CEO of Isomorphic Labs, in the release, 17 November 2026

“Our drug design engine is generating molecules with unprecedented precision and speed.”

Three Implications

FOR PHARMA PARTNERS Isomorphic says it runs partnered programs with Eli Lilly, Novartis and Johnson & Johnson alongside wholly-owned internal programs.

FOR AI DRUG-DISCOVERY RIVALS By our arithmetic, this one round is about 15 times the $332.5 million of healthcare AI rounds we counted from 1 October to 4 November.

RELATED DeepMind alumni have founded 57 startups that raised $10M or more, 15 of them UK-based.

The Business Engineer Lens

This story maps onto the Business Engineer framework The Four Intelligence Moats.

The framework says: “Each moat is built by a different data pipeline.”

As we read it, Isomorphic’s pipeline is the partner ecosystem on mechanistic disease biology and the preclinical data its release describes. The framework predates the round and does not discuss Isomorphic.

Bar chart: Isomorphic Labs Series C of $5,000 million against nearly $3,000 million of potential value and $82.5 million of upfront payments in its January 2024 Lilly and Novartis deals
Isomorphic’s $5 billion Series C against its January 2024 Eli Lilly and Novartis deals: $45 million and $37.5 million upfront, and nearly $3 billion of potential value excluding royalties, from the company’s releases. The more-than-60x ratio is our arithmetic. Not investment advice.

What Is Not Established

We could not read Bloomberg’s paywalled article, so we do not report its details; the round size, investors and plans here come from Isomorphic’s own release. The company’s release does not state a valuation, the size of each investor’s cheque or how much Alphabet put in.

The upfront and potential deal values are from January 2024; the terms of the Novartis expansion and the Johnson & Johnson collaboration are not in the pages we read. Isomorphic and Alphabet were not contacted for this piece.

This Week In The AI Supercycle

AI Lost Its Central Banker, the Lab Oligopoly, and the Future of Open Source

This week’s issue: the Nvidia leadership change, read as the AI build-out losing its central banker: who now finances the GPU landlords, backstops the data centres and sponsors open models, and why two labs are becoming the bank.

Read the full issue →

Business Engineer Framework

The Four Intelligence Moats

The Business Engineer framework on how each data pipeline becomes a moat in the AI stack, and how each moat decays.

Read the premium analysis →Get 50% off →

The Bottom Line

Isomorphic Labs has raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, 2.4 times its May round and about 65% of the $7.7 billion it has announced in external funding since March 2025, by our arithmetic. The release ties the money to its drug design engine and to taking its first programs towards clinical trials.

95,000+ executives read Business Engineer for the AI strategy frameworks cited by ChatGPT, Claude, and Perplexity.

A note on sourcing. We read Isomorphic Labs’ 17 November 2026 news release in full, and its earlier posts on the March 2025 and May 2026 rounds, the January 2024 Eli Lilly and Novartis collaborations, the January 2026 Johnson & Johnson collaboration and its partnerships page. Bloomberg’s article is paywalled and we did not read it; the 4 November valuation report is from our earlier piece, linked. The totals, ratios and percentages are our arithmetic. Not investment advice; for information only.

Sources: Isomorphic Labs news release (PDF), 17 Nov 2026 · Isomorphic Labs Series C post, 17 Nov 2026 · Isomorphic Labs Series B post, 12 May 2026 · Isomorphic Labs first external round, 31 Mar 2025 · Isomorphic Labs Lilly and Novartis post, 7 Jan 2024 · Isomorphic Labs partnerships page · Bloomberg on X, 17 Nov 2026

Scroll to Top
FourWeekMBA